Skip to content

Multi-Sequence MRI Evaluation of Glymphatic Function Following Fecal Microbiota Transplantation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome Comorbid with Anxiety/Depression

Multi-Sequence MRI Evaluation of Glymphatic Function Following Fecal Microbiota Transplantation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome Comorbid with Anxiety/Depression

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126877
Enrollment
Unknown
Registered
2026-06-17
Start date
2026-06-20
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel Syndrome

Interventions

Group of Fecal Microbiota Transplantation (FMT):none
non-FMT treatment group:none

Sponsors

Shenzhen Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Confirmed clinical diagnosis of diarrhea-predominant irritable bowel syndrome (IBS-D) fulfilling the Rome IV criteria; 2. Comorbid anxiety and/or depression, defined as a baseline score of >=50 on the Self-Rating Anxiety Scale (SAS) and/or the Self-Rating Depression Scale (SDS) during routine admission assessments; 3. Recent colonoscopy (within the previous 12 months) demonstrating normal findings, although minor abnormalities such as hemorrhoids or <= 3 polyps with a maximum diameter <=5 mm were permitted.

Exclusion criteria

Exclusion criteria: 1. Severe organic gastrointestinal or peripheral digestive system diseases (e.g., tuberculous peritonitis, pancreatitis, liver cirrhosis, biliary tract diseases), lactose intolerance, celiac disease, or other severe systemic conditions (e.g., significant cardiovascular, hepatic, or renal dysfunction, malignancies, autoimmune diseases, and metabolic disorders); 2. Severe psychiatric disorders other than anxiety and depression; 3. MRI contraindications or intolerance (e.g., claustrophobia), or the presence of = 5 ischemic white matter lesions on brain MRI; 4. Incomplete clinical or neuroimaging data, or poor MRI image quality; 5. Pregnancy, lactation, or current plans to conceive.

Design outcomes

Primary

MeasureTime frame
diffusion tensor image analysis along the perivascular space (ALPS) index ;Choroid Plexus Volume, CPV;White Matter Free-Water Volume Fraction, WM-FW;Perivascular Spaces Volume, PVS;Bristol Stool Scale, BBS;global blood-oxygen-level-dependent signal and cerebrospinal fluid inflow coupling, gBOLD-CSF;

Secondary

MeasureTime frame
Irritable Bowel Syndrome Symptom Severity Scale, IBS-SSS;Irritable Bowel Syndrome Quality of Life Questionnair, IBS-QOL;Self-Rating Anxiety Scale, SAS;Self-Rating Depression Scale, SDS;Numerical Rating Scale, NRS;

Countries

China

Contacts

Public ContactYubao Liu

Shenzhen Hospital of Southern Medical University

ybliu28@163.com+86 150 1672 2533

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 29, 2026